Search Within

Haley Frances Hauser

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (3)
Groups
  1. Center for Pancreatic Cancer Research (9)
  2. Department of Medicine (9)
  3. Epidemiology and Biostatistics (9)
  4. Gastrointestinal Oncology Service (9)
  5. Solid Tumor Oncology Division (9)
  6. Survivorship Research (9)

More Groups

People
  1. Joanne Chou (7)
  2. Diane Reidy (6)
  3. Marinela Capanu (6)
  4. Nitya Raj (5)
  5. Olivia Heffernan (5)
  6. Tiffany Le (5)

More People

Years
  1. 2022 (4)
  2. 2021 (1)
  3. 2020 (1)
  4. 2019 (2)
  5. 2018 (1)
Publications
  1. Journal of Clinical Oncology (4)
  2. Pancreas (2)
  3. Cancer Medicine (1)
  4. JAMA Oncology (1)
  5. JCO Oncology Practice (1)
Publishers
  1. American Society of Clinical Oncology (5)
  2. Lippincott Williams & Wilkins (2)
  3. American Medical Association (1)
  4. Wiley Blackwell (1)

Results (9)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment response and clinical outcomes of neuroendocrine neoplasms (NENs) treated with immune checkpoint inhibitors (ICIs): A single institution experience
    Meeting Abstract

    Hauser, H.; Le, T.; Chou, J. F.; Heffernan, O.; DeMore, A.; Gonen, S.; Capanu, M.; Reidy-Lagunes, D.; Raj, N.
    Pancreas (2022)

    Fulltext@MSK | Save
  • Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well- differentiated neuroendocrine tumors (WDNETs)
    Meeting Abstract

    Raj, N.; Cruz, E.; Chou, J.; Capanu, M.; DeMore, A.; Hauser, H.; Heffernan, O.; Le, T.; Saltz, L.; Reidy-Lagunes, D.
    Pancreas (2022)

    Fulltext@MSK | Save
  • A randomized trial evaluating patient experience and preference between octreotide long-acting release and lanreotide for treatment of well-differentiated neuroendocrine tumors
    Journal Article

    Raj, N.; Cruz, E.; O'Shaughnessy, S.; Calderon, C.; Chou, J. F.; Capanu, M.; Heffernan, O.; DeMore, A.; Punn, S.; Le, T.; more...
    JCO Oncology Practice (2022)

    Fulltext@MSK | Save
  • Treatment response and clinical outcomes of neuroendocrine neoplasms treated with immune checkpoint inhibitors: A single-institution experience
    Meeting Abstract

    Hauser, H.; Le, T.; Chou, J. F.; Heffernan, O.; DeMore, A.; Gonen, S.; Capanu, M.; Reidy, D. L.; Raj, N. P.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well differentiated neuroendocrine tumors (WDNETs)
    Meeting Abstract

    Raj, N. P.; Cruz, E.; Chou, J. F.; Capanu, M.; Heffernan, O.; Le, T.; Hauser, H.; Saltz, L. B.; Reidy, D. L.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: A phase 2 clinical trial
    Journal Article

    Cercek, A.; Boerner, T.; Tan, B. R.; Chou, J. F.; Gönen, M.; Boucher, T. M.; Hauser, H. F.; Do, R. K. G.; Lowery, M. A.; Harding, J. J.; more...
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion
    Journal Article

    Smith, J. J.; Chatila, W. K.; Sanchez-Vega, F.; Datta, J.; Connell, L. C.; Szeglin, B. C.; Basunia, A.; Boucher, T. M.; Hauser, H.; Wasserman, I.; more...
    Cancer Medicine (2019)

    Fulltext@MSK | Save
  • Randomized phase II trial of adjuvant hepatic arterial infusion (HAI) + systemic FOLFIRI +/- panitumumab (Pmab) in patients with resected RAS wild type colorectal cancer hepatic metastases (CRLM)
    Meeting Abstract

    Kemeny, N. E.; Hauser, H.; Capanu, M.; Kingham, T. P.; Jarnagin, W. R.; DeMatteo, R. P.; Cercek, A.; Balachandran, V. P.; Drebin, J. A.; D'Angelica, M. I.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin (GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC)
    Meeting Abstract

    Cercek, A.; Kemeny, N. E.; Boerner, T.; Tan, B. R.; Chou, J. F.; Gonen, M.; Boucher, T. M.; Hauser, H.; Do, R. K. G.; Lowery, M. A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save